Lipocine Inc's stock is trading higher after the company released positive topline results from a Phase 2 clinical study of LPCN 1148, a drug under development for the clinical management of cirrhosis. The study showed that patients treated with LPCN 1148 experienced significantly fewer cases of hepatic encephalopathy and reported significant improvement in symptoms. The drug was well-tolerated with adverse event rates similar to placebo.